The latest price target for Viridian Therapeutics (NASDAQ:VRDN) was reported by Wells Fargo on December 19, 2024. The analyst firm set a price target for $27.00 expecting VRDN to rise to within 12 months (a possible 39.82% upside). 36 analyst firms have reported ratings in the last year.

The latest analyst rating for Viridian Therapeutics (NASDAQ:VRDN) was provided by Wells Fargo, and Viridian Therapeutics downgraded their equal-weight rating.

There is no last upgrade for Viridian Therapeutics

The last downgrade for Viridian Therapeutics Inc happened on December 19, 2024 when Wells Fargo changed their price target from N/A to $27 for Viridian Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Viridian Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Viridian Therapeutics was filed on December 19, 2024 so you should expect the next rating to be made available sometime around December 19, 2025.

While ratings are subjective and will change, the latest Viridian Therapeutics (VRDN) rating was a downgraded with a price target of $0.00 to $27.00. The current price Viridian Therapeutics (VRDN) is trading at is $19.31, which is within the analyst’s predicted range.